Related Experiment Video
Updated: Apr 28, 2026
Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
Published on: February 2, 2024
Current concepts in the management of prosthetic joint infection
C Aboltins1, J Daffy, P Choong
1Department of Infectious Diseases, Northern Health, Melbourne, Victoria, Australia; Northwest Academic Centre, The University of Melbourne, Melbourne, Victoria, Australia.
Abstract:
Prosthetic joint infection (PJI) is a serious complication of arthroplasty that is associated with significant mortality, morbidity and costs. PJI is difficult to cure because causative bacteria form and persist in biofilm adherent to the prosthesis surface. PJI can be classified into early, delayed or late according to the time of onset after insertion of the prosthesis, and this classification can help determine pathogenesis and appropriate management. Traditional treatment has been with prolonged intravenous antibiotics and prosthesis exchange, which has been successful in treating infection but is technically difficult and has high rates of associated morbidity. On the basis of in vitro and animal studies, interest has turned to the use of antimicrobials that are particularly active against biofilm-associated bacteria. Recent clinical evidence shows success in more than 77% of early PJI with surgical debridement, retention of prosthesis and the use of rifampicin-based combinations for staphylococcal PJI. Fluoroquinolones are preferred for Gram-negative PJI. Optimal antimicrobial treatment duration and the management of polymicrobial, enterococcal, fungal and culture-negative infections are still yet to be defined but will become more clear as the results of current research comes to hand.
Insights
Prosthetic joint infection (PJI) is a challenging complication of arthroplasty. New research shows promising results for early PJI using debridement, prosthesis retention, and specific antibiotics like rifampicin or fluoroquinolones.
Area of Science:
- Orthopedics
- Infectious Diseases
- Microbiology
Background:
- Prosthetic joint infection (PJI) is a severe complication following arthroplasty, characterized by high mortality, morbidity, and economic burden.
- Bacteria forming biofilms on prosthesis surfaces present a significant challenge to eradicating PJI.
- Classifying PJI by onset time (early, delayed, late) aids in understanding pathogenesis and guiding management.
Purpose of the Study:
- To review current understanding and treatment strategies for prosthetic joint infections (PJI).
- To highlight the role of biofilm-forming bacteria in PJI persistence.
- To evaluate emerging antimicrobial treatments targeting biofilm-associated bacteria.
Main Methods:
- Review of in vitro and animal studies on biofilm-associated bacteria.
- Analysis of recent clinical evidence for PJI treatment.
- Classification of PJI based on time of onset.
Main Results:
- Surgical debridement with prosthesis retention and rifampicin-based combinations show over 77% success in early staphylococcal PJI.
- Fluoroquinolones are recommended for Gram-negative PJI.
- Optimal treatment durations and management for complex PJI cases remain under investigation.
Conclusions:
- Targeted antimicrobial therapy, particularly rifampicin combinations and fluoroquinolones, offers improved outcomes for specific PJI types.
- Further research is needed to define optimal treatments for polymicrobial, enterococcal, fungal, and culture-negative PJIs.
- Advances in understanding biofilm dynamics are crucial for developing more effective PJI therapies.
Related Concept Videos
01:29Endocarditis IV: Nursing Management
01:18Endocarditis III: Medical Management
01:17Urinary Tract Infection IV: Nursing Management
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management